Search | Médecins Sans Frontières Access Campaign

About us
About the Access Campaign

Some of our 2023 plans

Media room

Latest news

Jobs
Get Involved!
Sign up to stay updated and find out how you can get involved.

Email Address

Data protection consent

I want to receive emails from MSF and I have read and agree with the privacy policy.
Our work
COVID-19

Explainer: A bold proposal at the WTO by India and South Africa

Diabetes

Drug-resistant infections

HIV/AIDS

Hepatitis C

Hypertension

Patents and intellectual property

Pandemic prevention, preparedness and response

The Patent Oppositions Database

Research and development

Spotlight on: the Big Pharma double-dip

Transparency Matters: Clinical Trials Costs

Tropical and neglected diseases

Spotlight on: Snakebite

Tuberculosis

Vaccines

Explainer: COVID-19 vaccines - Recommendations for equitable access
Get Involved!
Sign up to stay updated and find out how you can get involved.

Email Address

Data protection consent

I want to receive emails from MSF and I have read and agree with the privacy policy.
Get involved
Campaign success stories

#NoMoreTears Johnson & Johnson Can you hear us?

A Fair Shot

Novartis 'Drop the case'

Trans-pacific Partnership (TPP)

Recent campaigns

Time for $5

No Patents in a Pandemic

Share the Tech - Save Lives
Take Action

Get Involved!
Sign up to stay updated and find out how you can get involved.

Email Address

Data protection consent

I want to receive emails from MSF and I have read and agree with the privacy policy.
Resources
Press releases

Statements

Letters

Opinion articles

Feature stories

Interviews

Blog

Newsletters

Publications

Research articles

Topic overview pages

Spotlight pages

Videos

Photo stories

Infographics

Events
Get Involved!
Sign up to stay updated and find out how you can get involved.

Email Address

Data protection consent

I want to receive emails from MSF and I have read and agree with the privacy policy.

Medicines shouldn’t be a luxury Take action

29 results found

Letter |

13 July 2023

CSO letter supporting Resolution 881/23 by Colombia on issuing a compulsory license for HIV drug dolutegravir

MSF co-signed a CSO letter to Colombia welcoming a resolution on issuing a compulsory license for HIV drug dolutegravir

Tags HIV/AIDSIntellectual property and trade HIV/AIDS Colombia

MSF staff prepares a dose of an experimental vaccine

Opinion article |

20 October 2017

Korea must do its part for global access to affordable medicines and vaccines

This week in Korea, the 16 countries of the Regional Comprehensive Economic Partnership (RCEP) agreement are meeting in Incheon for the 20th round of negotiations on this multilateral trade deal.

Tags Intellectual property and trade pneumococcal disease pneumococcal conjugate vaccinevaccines intellectual property & tradeRegional Comprehensive Economic Partnership (RCEP) ASEAN

Letter |

08 December 2016

Médecins Sans Frontiéres UNAIDS PCB Intellectual Property intervention

Tags HIV/AIDSIntellectual property and trade HIV/AIDS antiretroviral medicines intellectual property & tradeUN High Level Panel on Access to Medicines UNAIDS

Statement |

08 December 2016

Médecins Sans Frontières UNAIDS PCB Intellectual Property intervention

Tags Intellectual property and trade HIV/AIDS antiretroviral medicines intellectual property & tradeUN High Level Panel on Access to Medicines

Civil society demonstration against IP provisions in RCEP that can block access to affordable medicines. Protest was done during 6th RCEP negotiationin India, 2014.

Opinion article |

02 December 2016

On World AIDS Day, threat to access to medicines looms large

Today millions of people living with HIV in South-East Asia are receiving treatment and leading healthy lives thanks to affordable generic antiretroviral (ARVs) medicines.

Tags Intellectual property and trade HIV/AIDStuberculosis access to medicinesgeneric medicinesintellectual property & tradeRegional Comprehensive Economic Partnership (RCEP) World AIDS Day ASEAN

Statement |

27 July 2015

WIPO Standing Committee on the Law of Patents, 22nd Session

Tags Intellectual property and trade drug-resistant TBEbolahepatitis C World Health Organization

Metro advertisements for Doctors Without Borders, 2015.

Opinion article |

24 July 2015

TPP: Don’t trade away health

Tags Intellectual property and trade tuberculosishepatitis CHIV/AIDS evergreeningfree trade agreementintellectual property & tradeTrans-Pacific Partnership Agreement (TPP)

Thumbnail

Opinion article |

24 July 2015

Why the TPP trade deal is a threat to public health

Tags Intellectual property and trade HIV/AIDS free trade agreementgeneric medicinesintellectual property & tradeTrans-Pacific Partnership Agreement (TPP) Democratic Republic of the Congo

Statement |

03 November 2014

MSF responds to BMS commercial strategy for hepatitis C drug daclatasvir in developing countries

Tags Hepatitis CIntellectual property and trade hepatitis C daclatasvirdirect-acting antiviralssofosbuvir access to medicinesvoluntary licence Bristol-Myers Squibb

Statement |

30 April 2014

MSF responds to US Trade 301 Watch List

Tags Intellectual property and trade HIV/AIDS antiretroviral medicines evergreeningfree trade agreementTrans-Pacific Partnership Agreement (TPP)TRIPS PEPFARPHARMACEUTICAL Companies India

Statement |

02 April 2014

Submission to the US Trade Representative Regarding the 2014 Special 301 Review Process

Tags Intellectual property and trade HIV/AIDS antiretroviral medicines free trade agreementTrans-Pacific Partnership Agreement (TPP)TRIPS PEPFAR India

Statement |

27 June 2013

Oral Testimony at US Congressional Hearing: “A Tangle of Trade Barriers: How India’s Industrial Policy is Hurting U.S. Companies.”

Tags Intellectual property and trade HIV/AIDS antiretroviral medicines compulsory licencefree trade agreementuniversal access Novartis India

Opinion article |

15 April 2013

The EU must show leadership in the global fight against HIV/AIDS

Tags Intellectual property and trade HIV/AIDS European Commission

Opinion article |

30 November 2012

Canada’s role in ‘getting to zero’ on HIV

Canada’s role in ‘getting to zero’ on HIV

Tags HIV/AIDSIntellectual property and trade HIV/AIDS antiretroviral medicines Trans-Pacific Partnership Agreement (TPP) World AIDS Day

Statement |

21 August 2012

Bayer/Natco compulsory licence appeal – hearings postponed

Tags Intellectual property and trade HIV/AIDS compulsory licence Bayer India

Opinion article |

07 August 2012

Do No Harm: How a US-Led Free Trade Agreement Threatens the Prospects for an AIDS-Free Generation

Do No Harm: How a US-Led Free Trade Agreement Threatens the Prospects for an AIDS-Free Generation

Tags HIV/AIDSIntellectual property and trade HIV/AIDS antiretroviral medicines Trans-Pacific Partnership Agreement (TPP) International AIDS Conference

Opinion article |

27 July 2012

Right of people to affordable access to medicines

Tags HIV/AIDSIntellectual property and trade HIV/AIDS antiretroviral medicines International AIDS Conference Myanmar

Opinion article |

06 January 2012

False positive HIV tests: the problem no one wants to talk about (and how to solve it)

Tags HIV/AIDSIntellectual property and trade HIV/AIDS diagnostic tests ICASA

Opinion article |

05 January 2012

ICASA conference: donor retreat and its consequences for patients and communities

Tags HIV/AIDSIntellectual property and trade HIV/AIDS antiretroviral medicines ICASAPEPFAR

Opinion article |

03 January 2012

MSF: Initial outcomes of combination treatment for HIV and visceral leishmaniasis co-infection

Tags HIV/AIDSIntellectual property and tradeTropical & neglected diseases co-infectionHIV/AIDSvisceral leishmaniasis (kala azar) antiretroviral medicines ICASA Ethiopia